natgillin/translations-raw huggingface dataset:
om ændring af Rådets forordning (EF) nr. 2187/2005 for så vidt angår forbud mod high-grading og restriktioner i forbindelse med fiskeri efter skrubbe og pighvar i Østersøen, Bælterne og Øresund
amending Council Regulation (EC) No 2187/2005 as regards the prohibition of highgrading and restrictions on fishing for flounder and turbot in the Baltic Sea, the Belts and the Sound
Ved Rådets forordning (EF) nr. 2187/2005 [3] er der fastsat specifikke tekniske foranstaltninger til bevarelse af fiskeressourcerne i Østersøen, Bælterne og Øresund og navnlig restriktioner for fiskeri for så vidt angår visse arter, maskestørrelser og områder.
Council Regulation (EC) No 2187/2005 [3] lays down specific technical measures for the conservation of fishery resources in the Baltic Sea, the Belts and the Sound, and in particular restrictions on fishing as regards certain species, mesh sizes and areas.
Rådets forordning (EF) nr. 1226/2009 af 20. november 2009 om fastsættelse for 2010 af fiskerimuligheder og dertil knyttede betingelser for visse fiskebestande og grupper af fiskebestande for Østersøen [4] indeholder et forbud mod high-grading og restriktioner i forbindelse med fiskeri efter skrubbe og pighvar.
Council Regulation (EC) No 1226/2009 of 20 November 2009 fixing the fishing opportunities and associated conditions for certain fish stocks and groups of fish stocks applicable in the Baltic Sea for 2010 [4] provides for the prohibition of highgrading and for restrictions on fishing for flounder and turbot.
Forbuddet og restriktionerne er tekniske foranstaltninger af permanent karakter, der ikke længere bør indgå i den regulering, der fastsætter de årlige fiskerimuligheder.
This prohibition and these restrictions are technical measures of a permanent nature which should no longer be included in the regulatory framework establishing annual fishing opportunities.
Fra januar 2011 bør de derfor indarbejdes i forordning (EF) nr. 2187/2005.
From January 2011, they should therefore be incorporated into Regulation (EC) No 2187/2005.
Ordet »Fællesskab«, der anvendes i den dispositive del af forordning (EF) nr. 2187/2005 bør ændres som følge af Lissabontraktatens ikrafttræden den 1. december 2009.
The term ‘Community’ used in the enacting terms of Regulation (EC) No 2187/2005 should be changed following the entry into force of the Treaty of Lisbon on 1 December 2009.
Forordning (EF) nr. 2187/2005 bør ændres i overensstemmelse hermed.
Regulation (EC) No 2187/2005 should therefore be amended accordingly.
For at sikre den fortsatte anvendelse af foranstaltningerne i denne forordning, bør den træde i kraft dagen efter offentliggørelsen i Den Europæiske Unions Tidende —
In order to ensure the continuous application of the measures provided for in this Regulation, it should enter into force on the day following its publication in the Official Journal of the European Union,
I forordning (EF) nr. 2187/2005 foretages følgende ændringer:
Regulation (EC) No 2187/2005 is hereby amended as follows:
Følgende artikel indsættes:
the following article is inserted:
Alle kvoterede arter, der fanges under fiskeri, skal bringes om bord og efterfølgende landes, medmindre dette strider mod forpligtelser i Unionens fiskeriforordninger om tekniske foranstaltninger og kontrol- og bevaringsforanstaltninger, navnlig i nærværende forordning, i forordning (EF) nr. 2371/2002 eller i Rådets forordning (EF) nr. 1224/2009 af 20. november 2009 om oprettelse af en EF-kontrolordning med henblik på at sikre overholdelse af reglerne i den fælles fiskeripolitik.2) Følgende artikel indsættes:
Any species which is subject to a quota and which is caught during fishing operations shall be brought aboard the vessel and subsequently landed unless this would be contrary to obligations laid down in Union fisheries regulations establishing technical, control and conservation measures in particular in this Regulation, in Regulation (EC) No 2371/2002 or in Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring compliance with the rules of the common fisheries policy.2. the following article is inserted:
Det er forbudt at beholde fisk af nedenstående arter om bord, når de er fanget i følgende geografiske områder og perioder:
The retention on board of the following species of fish shall be prohibited where they are caught within the geographical areas and during the periods mentioned below:
Underafsnit 26, 27, 28 og 29 syd for 59° 30′ N
Subdivisions 26, 27, 28 and 29 south of 59° 30′ N
Underafsnit 25, 26 og 28 syd for 56° 50′ N
Subdivisions 25, 26 and 28 south of 56° 50′ N
Uanset stk. 1 er det, når der fiskes med trawl, snurrevod eller lignende redskaber med en maskestørrelse på mindst 105 mm eller med gællegarn, indfiltringsgarn eller toggergarn med en maskestørrelse på mindst 100 mm, tilladt at beholde bifangster af skrubbe og pighvar om bord og lande dem, hvis sådanne bifangster højst udgør 10 % udtrykt i levende vægt af den samlede fangst, der beholdes om bord og landes i de forbudsperioder, der er omhandlet i stk. 1.«.
By way of derogation from paragraph 1, when fishing with trawls, Danish seines or similar gears with a mesh size equal to or greater than 105 mm or with gillnets, entangling nets or trammel nets with a mesh size equal to or greater than 100 mm, by-catches of flounder and turbot may be retained on board and landed within a limit of 10 % by live weight of the total catch retained on board and landed during the periods of prohibition referred to in paragraph 1.’;
I artikel 26, stk. 1 og 2, erstattes ordene »Fællesskabets« og »fællesskabsretten« af henholdsvis »Unionens« og »EU-retten«, og de nødvendige grammatiske tilpasninger, der måtte følge af denne ændring, foretages.
in Article 26(1) and (2), the noun ‘Community’, or the corresponding adjective, is replaced by the noun ‘Union’, or the corresponding adjective, and any grammatical adjustments needed as a consequence of this replacement shall be made.
Europa-Parlamentets holdning af 23.11.2010 (endnu ikke offentliggjort i EUT) og Rådets afgørelse af 6.12.2010.
Position of the European Parliament of 23 November 2010 (not yet published in the Official Journal) and decision of the Council of 6 December 2010.
EUT L 343 af 22.12.2009, s. 1.«
OJ L 343, 22.12.2009, p. 1.’;
Europa-Parlamentets og Rådets forordning (EU) nr. 1238/2010
Regulation (EU) No 1238/2010 of the European Parliament and of the Council
om ændring af bilag I til forordning (EØF) nr. 2658/87 for så vidt angår sikring af toldfri behandling af visse aktive farmaceutiske ingredienser med internationale ikke-navnebeskyttede navne (INN) fra Verdenssundhedsorganisationen og af visse produkter, der anvendes til fremstilling af farmaceutiske færdigvarer
amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals
Under forhandlingerne i Uruguayrunden vedtog Fællesskabet og en række lande, at der bør indrømmes toldfri behandling for farmaceutiske varer henhørende under kapitel 30 i det harmoniserede system (HS) og HS-position 2936, 2937, 2939 og 2941 og for nærmere angivne aktive farmaceutiske ingredienser med internationale ikke-navnebeskyttede navne (INN) fra Verdenssundhedsorganisationen samt for nærmere angivne salte, estere og hydrater af sådanne INN og desuden for nærmere angivne farmaceutiske mellemstoffer, der anvendes til produktion og fremstilling af farmaceutiske færdigvarer.
In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty-free treatment should be granted to pharmaceutical products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization, specified salts, esters and hydrates of such INNs, and designated pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals.
Resultaterne af drøftelserne som gengivet i referatet blev indarbejdet i deltagernes toldlister, der er bilagt Marrakeshprotokollen til den almindelige overenskomst om told og udenrigshandel (GATT) 1994.
The results of the discussions, as set out in the Record of Discussions, were incorporated into the tariff schedules of the participants annexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (GATT) 1994.
Deltagerne konkluderede, at repræsentanter for de medlemmer af Verdenshandelsorganisationen (WTO), der deltog i drøftelserne, skulle mødes inden for rammerne af WTO's Råd for Handel med Varer, sædvanligvis mindst én gang hvert tredje år, for at revidere produktdækningen med henblik på ved konsensus at tilføje yderligere farmaceutiske produkter, der ikke længere skal belægges med told.
Participants concluded that representatives of World Trade Organization (WTO) members, party to the Record of Discussions, would meet under the auspices of the Council for Trade in Goods of the WTO, normally at least once every three years, to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination.
Tre sådanne revisioner har fundet sted, og resultatet er, at der er indrømmet behandling med toldfritagelse af yderligere et bestemt antal INN og farmaceutiske mellemstoffer, der bruges til produktion og fremstilling af farmaceutiske færdigvarer, at nogle af disse mellemstoffer er overført til listen over INN, og at listen over nærmere bestemte præfikser og suffikser for salte, estere eller hydrater af INN er blevet udvidet.
Three such reviews have taken place with the result that a certain number of additional INNs and pharmaceutical intermediates used for the production and manufacture of finished pharmaceuticals have been granted duty-free treatment, that some of those intermediates have been transferred to the list of INNs, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs has been expanded.
Ved Rådets forordning (EØF) nr. 2658/87 af 23. juli 1987 om told- og statistiknomenklaturen og den fælles toldtarif [2] blev den kombinerede nomenklatur (KN) indført og den fælles toldtarifs konventionelle toldsatser fastsat.
Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff [2] established the Combined Nomenclature (CN) and set out the conventional duty rates of the Common Customs Tariff.
For at sikre, at de i denne forordning fastsatte foranstaltninger anvendes fra den 1. januar 2011, bør denne forordning træde i kraft på dagen efter offentliggørelsen —
In order to ensure that the measures provided for in this Regulation apply from 1 January 2011, it should enter into force on the day following that of its publication,
Bilag 3, 4 og 6 i afsnit II i del III i bilag I til forordning (EØF) nr. 2658/87 (lister over farmaceutiske stoffer, som opfylder betingelserne for behandling med toldfritagelse) ændres således:
Annexes 3, 4 and 6 of Section II of Part Three of Annex I to Regulation (EEC) No 2658/87 (Lists of pharmaceutical substances which qualify for duty-free treatment) are hereby amended as follows:
Fra den 1. januar 2011 indrømmer Unionen toldfritagelse for de i bilag I angivne INN.
As from 1 January 2011 the Union shall extend duty-free treatment to the INNs listed in Annex I.
Listen over præfikser og suffikser, som i forbindelse med de anførte INN, der er tilføjet i det farmaceutiske sektorarrangement med senere ændringer, beskriver de salte, estere eller hydrater af INN, som også er berettigede til behandling med toldfritagelse, under forudsætning af at disse kan tariferes i samme 6-cifrede HS-underposition som det tilsvarende INN, ændres fra den 1. januar 2011 som anført i bilag II.
As from 1 January 2011 the list of prefixes and suffixes which, in combination with the INNs included in the pharmaceutical sectoral arrangement and its revisions, describe the salts, esters or hydrates of INNs which are also eligible for duty-free treatment, on condition that they are classifiable in the same six-digit HS subheading as the corresponding INN, shall be amended as set out in Annex II.
Fra den 1. januar 2011 indrømmer Unionen toldfritagelse for de farmaceutiske mellemstoffer, der anvendes til produktion og fremstilling af de farmaceutiske færdigvarer, og som er opført i bilag III.
As from 1 January 2011 the Union shall extend duty-free treatment to the pharmaceutical intermediates used in the production and manufacture of finished pharmaceuticals, listed in Annex III.
Fra den 1. januar 2011 skal de farmaceutiske mellemstoffer, der er opført i bilag IV, slettes på listen over de stoffer, som er fritaget for told.
As from 1 January 2011 the pharmaceutical intermediates listed in Annex IV shall be withdrawn from the list of such compounds receiving duty-free treatment.
Liste over internationale ikke-navnebeskyttede navne (INN), der skal tilføjes på listen over produkter, der er fritaget for told, i bilag 3 til bilag I til forordning (EØF) nr. 2658/87
List of international non-proprietary names (INNs) to be added to the list of products receiving duty-free treatment included in Annex 3 to Annex I to Regulation (EEC) No 2658/87
iodfiltinsyre (123
iodofiltic acid (123
cholinfenofibrat
choline fenofibrate
arbaclofenplacarbil
arbaclofen placarbil
carisbamat
carisbamate
gabapentinenacarbil
gabapentin enacarbil
incyclinid
incyclinide
alcaftadin
alcaftadine
imisopasemmangan
imisopasem manganese
ferroquin
ferroquine
intiquinatin
intiquinatine
brivanibalaninat
brivanib alaninate
disitertid
disitertide
isavuconazoniumchlorid
isavuconazonium chloride
managlinatdialanetil
managlinat dialanetil
aclidiniumbromid
aclidinium bromide
amolimogenbepiplasmid
amolimogene bepiplasmid
azilsartanmedoxomil
azilsartan medoxomil
beperminogenperplasmid
beperminogene perplasmid
fosalvudintidoxil
fosalvudine tidoxil
idrabiotaparinuxnatrium
idrabiotaparinux sodium
omacetaxinmepesuccinat
omacetaxine mepesuccinate
pramiconazol
pramiconazole
velimogenaliplasmid
velimogene aliplasmid
lodenafilcarbonat
lodenafil carbonate
levomefolinsyre
levomefolic acid
tridecactid
tridecactide
dexamethasoncipecilat
dexamethasone cipecilate
fluticasonfuroat
fluticasone furoate
methylnaltrexonbromid
methylnaltrexone bromide
darotropiumbromid
darotropium bromide
ferricarboxymaltose
ferric carboxymaltose
remogliflozinetabonat
remogliflozin etabonate
sergliflozinetabonat
sergliflozin etabonate
ceftarolinfosamil
ceftaroline fosamil
semuloparinnatrium
semuloparin sodium
(let kæde)
(light chain)
(tung kæde)
(heavy chain)
citatuzumabbogatox
citatuzumab bogatox
naptumomabestafenatox
naptumomab estafenatox
tucotuzumabcelmoleukin
tucotuzumab celmoleukin
vatreptacog alfa (aktiveret)
vatreptacog alfa (activated)
alacizumabpegol
alacizumab pegol
verpasepcaltespen
verpasep caltespen
alferminogentadenovec
alferminogene tadenovec
alipogentiparvovec
alipogene tiparvovec
contusugenladenovec
contusugene ladenovec
sitimagenceradenovec
sitimagene ceradenovec
transferrinaldifitox
transferrin aldifitox
azoximerbromid
azoximer bromide
Liste over præfikser og suffikser, som i forbindelse med de i bilag 3 til bilag I til forordning (EØF) nr. 2658/87 nævnte INN beskriver salte, estere eller hydrater af INN; disse salte, estere og hydrater er fritaget for told, forudsat at de kan tariferes i samme 6-cifrede HS-underposition som det tilsvarende INN
List of prefixes and suffixes which, in combination with the INNs of Annex 3 to Annex I to Regulation (EEC) No 2658/87, describe the salts, esters or hydrates of INNs; these salts, esters and hydrates are free of duty, on condition that they are classifiable in the same six-digit HS subheading as the corresponding INN
Henvisningerne til »International Nonproprietary Names (INN) for pharmaceutical substances, names for radicals and groups, comprehensive list 2004« erstattes af henvisninger til »International Nonproprietary Names (INN) for pharmaceutical substances, names for radicals, groups and others, comprehensive list 2007«.
The references to ‘International Nonproprietary Names (INN) for pharmaceutical substances, names for radicals and groups, comprehensive list 2004’ are replaced by ‘International Nonproprietary Names (INN) for pharmaceutical substances, names for radicals, groups and others, comprehensive list 2007’.
Følgende præfikser eller suffikser tilføjes til listen i bilag 4 til bilag I til forordning (EØF) nr. 2658/87:
The following prefixes or suffixes are added to the list included in Annex 4 to Annex I to Regulation (EEC) No 2658/87:
alaninat (INNRG)
alaninate (INNRG)
L-alaninat (INNCN)
L-alaninate (INNCN)
(4-iminobutan-1,4-diyl)sulfandiyl[(3RS)-2,5-dioxopyrrolidin-1,3-diyl]-1,3-phenylencarbonyl, som danner et N-benzoylderivat med en gruppe af primære aminer af difteri-[550-L-phenylalanin]toksin fra Corynebacterium diphtheriae-(26-560)-peptid (INNCN)
(4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl and forming an N-benzoyl derivative of a primary amine group of diphtheria [550-L-phenylalanine]toxin from Corynebacterium diphtheriae-(26-560)-peptide (INNCN)
L-lysyl-L-alanyl-L-serylglycylglycin (linker) fusionsprotein med des-(365-380)-[Asn364,Val407,Ser515,Gln590, Gln606,Arg613]exotoksin A (Pseudomonas aeruginosa)-(251-613)-peptid (toksin, hvor region IA og de første 16 rester af region IB er deleteret) (INNCN)
L-lysyl-L-alanyl-L-serylglycylglycine (linker) fusion protein with des-(365-380)-[Asn364,Val407,Ser515,Gln590,Gln606,Arg613]exotoxin A (Pseudomonas aeruginosa)-(251-613)-peptide (toxin with region IA and first 16 residues of region IB deleted) (INNCN)
ceribat (INNRG)
ceribate (INNRG)
rac-2,3-dihydroxypropylcarbonat (ester) (INNCN)
rac-2,3-dihydroxypropyl carbonate (ester) (INNCN)
cipecilat (INNRG)
cipecilate (INNRG)
cyclohexancarboxylat (ester), cyclopropancarboxylat (ester) (INNCN)
cyclohexanecarboxylate (ester), cyclopropanecarboxylate (ester) (INNCN)
des-B30-alanin (INNCN)
des-B30-alanine (INNCN)
glycylglycyl-L-prolin (linker) fusionsprotein med enterotoksin type A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222, Ser224]enterotoksin type E (Staphylococcus aureus)-(32-230)-peptid (syntetisk superantigen SEA/E-120) (INNCN)
glycylglycyl-L-proline (linker) fusion protein with enterotoxin type A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type E (Staphylococcus aureus)-(32-230)-peptide (synthetic superantigen SEA/E-120) (INNCN)
etexilat (INNRG)
etexilate (INNRG)
glucuronid (INNRG)
glucuronide (INNRG)
β-D-glucopyranosiduronsyre [osid] (INNCN)
β-D-glucopyranosiduronic acid [oside] (INNCN)
De systematiske navne af følgende præfikser eller suffikser ændres således:
The systematic name of the following prefix or suffix is amended as follows:
ricins A-kæde (INNCN)
ricin A chain (INNCN)
Liste over farmaceutiske mellemstoffer, dvs. stoffer der bruges til fremstilling af farmaceutiske færdigvarer, der skal tilføjes til listen over produkter, der er fritaget for told, i bilag 6 til bilag I til forordning (EØF) nr. 2658/87
List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be added to the list of products receiving duty-free treatment included in Annex 6 to Annex I to Regulation (EEC) No 2658/87
[4-amino-N-(pyrimidin-2(1H)-yliden-κN1)benzensulfonamidato-κO]sølv
[4-amino-N-(pyrimidin-2(1H)-ylidene-κN1)benzenesulfonamidato-κO]silver
(2R,3R)-2,3-dimethylbutan-1,4-diylbis(4-methylbenzensulfonat)
(2R,3R)-2,3-dimethylbutane-1,4-diyl bis(4-methylbenzenesulfonate)
4-chlorbutyl-2-nitrobenzensulfonat
4-chlorobutyl 2-nitrobenzenesulfonate
4-(5-brom-2-chlorbenzyl)phenylethylether
4-(5-bromo-2-chlorobenzyl)phenyl ethyl ether
2-[2-(2,2,2-trifluorethoxy)phenoxy]ethylmethansulfonat
2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl methanesulfonate
(2R)-2-(3-chlorphenyl)oxiran
(2R)-2-(3-chlorophenyl)oxirane
(2R)-2-[(5-brom-2,3-difluorphenoxy)methyl]oxiran
(2R)-2-[(5-bromo-2,3-difluorophenoxy)methyl]oxirane
[(2R)-2-methyloxiran-2-yl]methyl 4-nitrobenzensulfonat
[(2R)-2-methyloxiran-2-yl]methyl 4-nitrobenzenesulfonate
4′-(trifluormethyl)biphenyl-4-carbaldehyd
4′-(trifluoromethyl)biphenyl-4-carbaldehyde
iodmethylpivalat
iodomethyl pivalate
(3R)-3-methylhexansyre
(3R)-3-methylhexanoic acid
natrium-2-propylpentanoat
sodium 2-propylpentanoate
1-(2-ethylbutyl)cyclohexancarbonylchlorid
1-(2-ethylbutyl)cyclohexanecarbonyl chloride
1-(2-ethylbutyl)cyclohexancarboxylsyre
1-(2-ethylbutyl)cyclohexanecarboxylic acid
trans-4-(propan-2-yl)cyclohexancarboxylsyre
trans-4-(propan-2-yl)cyclohexanecarboxylic acid
natriumhydrogen-3-sulfonatobenzoat
sodium hydrogen 3-sulfonatobenzoate
diethylethyl(pentan-2-yl)propandioat
diethyl ethyl(pentan-2-yl)propanedioate
5′-chlor-2′-hydroxy-3′-nitrobiphenyl-3-carboxylsyre
5′-chloro-2′-hydroxy-3′-nitrobiphenyl-3-carboxylic acid
(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)(oxo)eddikesyre
(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)(oxo)acetic acid
2,5-bis(2,2,2-trifluorethoxy)benzoesyre
2,5-bis(2,2,2-trifluoroethoxy)benzoic acid
(3α,5β)-3-hydroxy-7-oxocholan-24-syre
(3α,5β)-3-hydroxy-7-oxocholan-24-oic acid
ethyl-2-[4-(2,2-dichlorcyclopropyl)phenoxy]-2-methylpropanoat
ethyl 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoate
methyl-3-(5-[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl-2-hydroxyphenyl)propanoat
methyl 3-(5-[4-(cyclopentyloxy)-2-hydroxyphenyl]carbonyl-2-hydroxyphenyl)propanoate
(1R)-1-[3,5-bis(trifluormethyl)phenyl]-N-methylethanamin
(1R)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanamine
(1R,2S)-2-(3,4-difluorphenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoat
(1R,2S)-2-(3,4-difluorophenyl)cyclopropanaminium (2R)-hydroxy(phenyl)ethanoate
2-(2,3-dihydro-1H-inden-2-yl)propan-2-aminhydrochlorid
2-(2,3-dihydro-1H-inden-2-yl)propan-2-amine hydrochloride
2-(4-chlor-3-ethylphenyl)ethanaminhydrochlorid
2-(4-chloro-3-ethylphenyl)ethanamine hydrochloride
N-(4-tert-butylbenzyl)-2-(4-chlor-3-ethylphenyl)ethanamin
N-(4-tert-butylbenzyl)-2-(4-chloro-3-ethylphenyl)ethanamine
N4-[(4-fluorphenyl)methyl]-2-nitro-1,4-benzendiamin
N4-[(4-fluorophenyl)methyl]-2-nitro-1,4-benzenediamine
(2R)-1-(5-brom-2,3-difluorphenoxy)-3-[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]aminopropan-2-ol hydrochlorid
(2R)-1-(5-bromo-2,3-difluorophenoxy)-3-[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]aminopropan-2-ol hydrochloride
[2-(chlormethyl)-4-(dibenzylamino)phenyl]methanolhydrochlorid
[2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydrochloride
antimonsyre – 1-deoxy-1-(methylamino)-D-glucitol (1:1)
antimonic acid – 1-deoxy-1-(methylamino)-D-glucitol (1:1)
ethyl-(2E)-3-(3-[(2R)-3-[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino-2-hydroxypropyl]oxy-4,5-difluorphenyl)prop-2-enoathydrochlorid
ethyl (2E)-3-(3-[(2R)-3-[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino-2-hydroxypropyl]oxy-4,5-difluorophenyl)prop-2-enoate hydrochloride
ethyl-3-(3-[(2R)-3-[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino-2-hydroxypropyl]oxy-4,5-difluorphenyl)propanoathydrochlorid
ethyl 3-(3-[(2R)-3-[1-(2,3-dihydro-1H-inden-2-yl)-2-methylpropan-2-yl]amino-2-hydroxypropyl]oxy-4,5-difluorophenyl)propanoate hydrochloride
2-[4-(aminomethyl)phenoxy]-N,N-dimethylethanamin
2-[4-(aminomethyl)phenoxy]-N,N-dimethylethanamine
(2E)-4-(dimethylamino)but-2-ensyrehydrochlorid
(2E)-4-(dimethylamino)but-2-enoic acid hydrochloride
(3S,5R)-3-amino-5-methyloctansyre
(3S,5R)-3-amino-5-methyloctanoic acid
(3S,5R)-3-amino-5-methyloctansyrehydrochlorid
(3S,5R)-3-amino-5-methyloctanoic acid hydrochloride
4-(1-aminocyclopropyl)-2,3,5-trifluorbenzoesyre
4-(1-aminocyclopropyl)-2,3,5-trifluorobenzoic acid
4-fluor-L-leucin – ethylhydrogensulfat (1:1)
4-fluoro-L-leucine – ethyl hydrogen sulfate (1:1)
methyl-2-(dimethylamino)-2-phenylbutanoat
methyl 2-(dimethylamino)-2-phenylbutanoate
methyl-3′-aminobiphenyl-3-carboxylat
methyl 3′-aminobiphenyl-3-carboxylate